Form 4: Maravai LifeSciences Director Gregory T. Lucier Reports Acquisition of 20,645 Shares

Gregory T. Lucier, a director at Maravai LifeSciences Holdings, Inc., reported acquiring 20,645 shares of Class A Common Stock at $10.78 per share on May 23, 2024, and was granted restricted stock units.

Summary

• On May 23, 2024, Gregory T. Lucier, a director of Maravai LifeSciences Holdings, Inc., acquired 20,645 shares of Class A Common Stock.
• The price per share was $10.78.
• Following the transaction, Lucier directly owns 75,768 shares of Class A Common Stock.
• Lucier was also granted restricted stock units which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The purchase itself is a slightly positive signal, but the filing is routine.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to the director's stock purchase.

Key Dates